Effects of adult growth hormone deficiency and replacement therapy on the cardiometabolic risk profile

Balázs Ratku1,2,3 · Veronika Sebestyén1,2 · Annamária Erdei4 · Endre V. Nagy4 · Zoltán Szabó1 · Sándor Somodi1,4*

Abstract
Adult growth hormone deficiency (AGHD) is considered a rare endocrine disorder involving patients with childhood-onset and adult-onset growth hormone deficiency (AoGHD) and characterized by adverse cardiometabolic risk profile. Besides traditional cardiovascular risk factors, endothelial dysfunction, low-grade inflammation, impaired adipokine profile, oxidative stress and hypovitaminosis D may also contribute to the development of premature atherosclerosis and higher cardiovascular risk in patients with AGHD. Growth hormone replacement has been proved to exert beneficial effects on several cardiovascular risk factors, but it is also apparent that hormone substitution in itself does not eliminate all cardiometabolic abnormalities associated with the disease. Novel biomarkers and diagnostic techniques discussed in this review may help to evaluate individual cardiovascular risk and identify patients with adverse cardiometabolic risk profile. In the absence of disease-specific guidelines detailing how to assess the cardiovascular status of these patients, we generally recommend close follow-up of the cardiovascular status as well as low threshold for a more detailed evaluation.

Keywords Growth hormone deficiency · Cardiometabolic risk · Growth hormone replacement therapy · Premature atherosclerosis

Introduction
Adult growth hormone deficiency (AGHD) is a distinct clinical syndrome affecting 200–300 people per million of the population [1]. The disease is characterized by reduced quality of life (QoL) and physical performance, osteoporosis and a coexistence of several cardiovascular risk factors including visceral obesity, adverse lipid profile, endothelial dysfunction and insulin resistance which together with other factors contribute to the higher rates of vascular events as well as excess mortality in hypopituitarism [2–5]. Extensive research of the past decades has shown that AGHD is associated with a low-grade inflammation, oxidative damage, thrombotic tendency, impaired adipokine profile, subclinical left ventricular (LV) dysfunction and high prevalence of metabolic syndrome (MetS) [6–11]. Growth hormone replacement therapy (GHRT) is now considered a safe treatment with beneficial effects on several cardiovascular risk factors, regardless of the underlying cause of GHD [12, 13]. Even though the impact of growth hormone therapy on the cardiovascular mortality of hypopituitarism is still far from being fully elucidated, complex hormone replacement including GH substitution is suggested to result in a mortality that is close to normal [4]. Despite GHRT has been available for more than two decades, disparities regarding the management of AGHD are still substantial [1] indicating that raising the awareness towards the deleterious consequences of the disease as well as the effects of replacement therapy may benefit the patients and may also benefit healthcare professionals.

The aim of this review is to deepen the understanding of the cardiovascular aspects of AGHD, to evaluate the effects of growth hormone replacement on the conventional and
novel cardiovascular risk factors, to summarize possible modalities of cardiovascular assessment and to encourage further research in the field.

Etiology of AGHD

Reduced growth hormone secretion in adulthood can result from pituitary and peri-pituitary tumors, impairment of hypothalamic-pituitary neuroendocrine pathways or local circulatory disturbance associated with surgery, radiotherapy or traumatic brain injury (TBI) [14, 15]. Based on the large international surveillance databases, pituitary adenomas and craniopharyngiomas account for more than half of the cases of AGHD, while idiopathic GHD, Sheehan’s syndrome and TBI are listed as less frequent causes [16]. Although pituitary tumors and their treatment have been consistently reported as frequent causes of AGHD, in the past decade an increasing number of studies revealed that certain non-classical causes of AGHD such as aneurysmal subarachnoid hemorrhage, infections of the central nervous system, sports-related repetitive head trauma and ventricular arrhythmias might be more frequent than previously thought [17]. Childhood-onset GHD (CoGHD) represents approximately 20% of all AGHD cases [18, 19]. GHD in childhood can be classified as idiopathic and organic GHD, with the latter involving congenital and acquired cases [20]. While hormone secretion in patients with idiopathic deficiency often recovers, patients with organic deficiency commonly remain GH deficient in adulthood [19, 20]. Importantly, childhood cancer survivors, especially those who received irradiation, are at greater risk for GHD, which may develop years or even decades after exposure to radiotherapy [14, 21]. The main causes of AGHD are listed in Table 1.

Cardiovascular system in AGHD

The GH/IGF-1 axis has an important role in regulating the vascular tone and maintaining the normal endothelial function [23]. Insulin-like growth factor 1 (IGF-1) and GH decrease peripheral resistance through peripheral and central mechanisms [23]. The peripheral actions can be subdivided into endothelial and non-endothelial mechanisms. In endothelial cells, IGF-1 increases the production and release of nitric oxide (NO), which causes smooth muscle relaxation and vasodilation [23, 24]. NO protects the endothelium from atherogenic changes by inhibiting proliferation and migration of smooth muscle cells, reducing LDL-oxidation and inhibiting platelet activation [23–26]. Physiologic NO levels also facilitate vascular repair and angiogenesis [27]. The non-endothelial actions of GH/IGF-1 axis involve stimulating the Na–K-ATPase activity and regulating the expression of the ATP sensitive potassium channel in the vascular smooth muscle [23, 28, 29]. Central regulatory effect via the sympathetic nervous system also contribute to the decrease of peripheral resistance [23, 30]. Moreover, the GH/IGF-1 axis has been suggested to protect the arteries from age-associated changes such as wall thickening and arterial stiffness [31].

In addition to its antiatherogenic and vasculoprotective properties, GH/IGF-1 axis has a considerable effect on the cardiac growth and metabolism [24]. IGF-1 favorably influences the trophic status of the heart by preventing cardiomyocyte apoptosis and promoting hypertrophy of cardiac

Table 1  Main causes of AGHD [14, 17, 19, 20, 22]

| Causes of AGHD                                                                 |
|--------------------------------------------------------------------------------|
| **Adult-onset growth hormone deficiency (AoGHD)**                               |
| Pituitary adenomas and their treatment                                         |
| Peri-pituitary tumors: craniofaryngioma, meningioma, glioma, metastasis        |
| Irradiation: cranial, craniospinal or total body irradiation                    |
| Sheehan’s syndrome                                                             |
| Traumatic brain injuries                                                      |
| Vascular catastrophes: aneurysmal subarachnoid hemorrhage, surgery, stroke     |
| Central nervous system infections: bacterial/viral/fungal meningitis            |
| Infiltrative diseases: sarcoidosis, tuberculosis, histiocytosis                |
| Immunologic disorders: lymphocytic hypophysitis                                |
| Empty sella syndrome                                                          |
| Idiopathic                                                                     |
| **Childhood-onset growth hormone deficiency (CoGHD)**                          |
| Congenital defects: anatomical anomalies, genetic disorders                    |
| Acquired disorders: tumors, surgery, irradiation, infiltrative diseases, brain injury |
| Idiopathic                                                                     |
Concerning functional effects, GH/IGF-1 axis has been demonstrated to reduce cardiac wall stress and increase contractility [33]. Postulated mechanisms underlying increased contractility involve modulation of intracellular Ca\(^{2+}\) levels, increased myofilament sensitivity to Ca\(^{2+}\) and upregulation of sarcoplasmic reticulum ATPase (SERCA) levels [34–37]. Furthermore, GH reduces the energy demand of the contractile process through promoting a shift towards V3 myosin isoform, which has a lower ATP-ase activity [23]. The most important physiological effects of GH/IGF-1 axis on the cardiovascular system is summarized in Fig. 1.

**Myocardial structure and function in AGHD**

In the past three decades several clinical studies have demonstrated the role of GH in the maintenance of physiological cardiac performance. In an early study, Cittadini et al. found impaired systolic function in untreated adults with CoGHD and detected considerable improvement in cardiac index after 6 months of GHRT [38]. Longobardi et al. reported similar abnormalities in LV function. Based on their findings, patients with AoGHD and CoGHD are not affected differently [39]. Likewise, Amato et al. found significant impairment of LV function as well as reduction of LV mass in GHD patients. Importantly, echocardiographic findings were completely back to normal in response to 6 months of GHRT but disappeared after 6 months of withdrawal [40]. Besides improved cardiac output and stroke volume (SV), Caidahl et al. demonstrated a decrease in diastolic blood pressure (DBP) with 6 months of GHRT [41]. Thuesen et al. conducted the first study in which the cardiovascular function was monitored for a relatively long period of time (38 months). Findings of this study suggested that long-term GHRT results in a normalization of cardiac structure, but the cardiac index and heart rate increased to supernormal levels [42]. Valcavi et al. demonstrated a clear increase in LV mass as well as reversal of diastolic abnormalities after 6 and 12 months of GHRT. All favorable changes disappeared with a 3-month withdrawal, but the increase in LV mass was still detectable [43]. In contrast, another study did not demonstrate LV hypertrophy even after 3–5 years of GHRT [44]. In 2003, a meta-analysis (n = 468) reported positive effect of GHRT on LV mass, LV end-diastolic diameter (LVEDD), intraventricular septum (IVS) thickness and SV; however, hormone substitution was not found to have a significant effect on systolic parameters [45].

These so-called historical studies frequently demonstrated inconsistent findings, which at least partially stem from the heterogeneity of study models and the differences in the administered GH doses, duration of replacement therapy and age of the enrolled patients [46, 47]. Additionally, conventional echocardiography, employed in the majority of these trials, is not considered sensitive enough to detect subtle impairment of LV function [47]. A few studies conducted in the past decade employed cardiac magnetic resonance imaging (CMRI) to evaluate the effect of GHRT. Andreasen et al. conducted the first study employing CMRI and found significantly smaller LV end-systolic and end-diastolic volumes and a trend towards reduced SV in untreated
patients compared to healthy subjects; significant association between baseline LV mass index and IGF-1 was also detected. 1-year GHRT resulted in a trend towards an increase in LV mass index, but no significant changes were detected in the cardiac mass [48]. Another notable study reported reduced cardiac mass in AoGHD patients and a significant increase in LV mass index with 1 year of GHRT. Furthermore, untreated GHD patients were also demonstrated to have reduced aortic area; however, this alteration did not change with 1-year GHRT. Significant changes of the right ventricular parameters were not found either [49]. Gonzalez et al. employed echocardiography, CMRI and cardiovascular exercise testing and experienced higher systolic blood pressure (SBP), ejection fraction (EF) and LV mass in AGHD patients with no changes in exercise capacity, systolic function and cardiac structure after 9 months of GHRT [50]. More recently, De Cobelli et al. have demonstrated reduced LV mass with normal resting systolic function as well as subclinical diastolic dysfunction in untreated GHD patients. Late gadolinium enhancement, a useful marker of structural abnormalities, was also evaluated: none of the patients showed any pathological areas within the heart [51].

In order to overcome the limitations of conventional 2DE echocardiography, Mihaila et al. employed two-dimensional speckle-tracking echocardiography (2D STE). Despite the fact that conventional echocardiography revealed normal LV systolic function, 2D STE demonstrated impaired LV longitudinal, circumferential and torsion functions in all patients with GHD [9]. In a small sample of patients with GHD, Boscetti et al. found reduced values of coronary flow reserve (CFR), an early marker of impaired myocardial microcirculation, and detected improvement in response to 1-year GHRT [52]. Finally, the most recent meta-analysis confirmed that GHRT was associated with increased EF and found positive effects on the thickness of the IVS and the LV posterior wall (LVPW) and decreased LV end-diastolic volume (LV EDV) which in conjunction with reduction of NT-BNP levels indicated improved systolic function in AGHD patients [53].

**Vascular changes in AGHD**

Published results show some controversy concerning blood pressure in GHD patients, but it seems that older patients have a slightly higher risk of developing hypertension. A large cross-sectional study (n = 926), which mainly consisted of patients with AoGHD, reported higher incidence of hypertension compared to general population (22.1 vs. 14.9%) [54] while studies recruiting young patients demonstrated unchanged or even lower blood pressure [38, 40]. The phenomenon of low blood pressure probably resulting from reduced extracellular water volume and low cardiac output has been observed in patients with CoGHD and has not been experienced in adults [55].

Several studies including two meta-analyses demonstrated beneficial effects of long-term GHRT on DBP [53, 56] and improvements are generally explained by the NO-mediated decrease of peripheral resistance and decreased intimal-medial thickness [41]. Concerning the 24-h blood pressure pattern, one study reported high incidence (37.03%) of non-dippers among GHD patients [55] while another study found no changes in the circadian rhythm of blood pressure and heart rate but observed reduction in SBP and DBP after 12 months of GHRT [57].

GHD is associated with premature atherosclerosis [58]. In the process of atherosclerosis, increased carotid intima-media thickness (CIMT), which has long been reported in GHD patients, is considered one of the earliest morphological changes of atherosclerosis [47, 58, 59]. In a prospective study, 1-year GHRT resulted in a significant decrease in CIMT, and the decrement was detected in 21 out of 22 patients [60]. Restoration of CIMT seems to be a relatively early and sustained beneficial effect of GHRT, and it was already observed after 6 months of GHRT [61] and maintained even after 10 years [62]. Other markers of endothelial dysfunction including reduced aortic distensibility as well as decreased flow-mediated endothelium dependent vasodilatation were also reported in GHD [63, 64].

**Lipid profile**

Dyslipidemia is considered the most significant contributor of adverse cardiovascular risk in hypopituitary patients [65]. Based on a cross-sectional observational study, lipid abnormalities in GHD include higher total cholesterol (TC), LDL-C and triglyceride levels in both sexes, and reduced HDL and Apo A-1 in women [65]. Concerning the effect of GHRT on lipid levels, two meta-analyses reported significant reduction in LDL-C level, one of them also found reduction in TC whereas neither of them demonstrated an increase in HDL-C [56, 66]. On the other hand, a 2-year observational study reported a decrease in LDL-C and TC levels after 6-month GHRT while an increase in HDL-C became significant only after 18 months of GHRT indicating that HDL-C levels may take more time to increase [67]. The latter is also supported by a long-term (15 years) prospective study which demonstrated significant sustained increment of HDL-C levels [68]. As for the triglyceride levels, a 5-year prospective study observed some reduction after years of GHRT, while other studies and a meta-analysis did not [56, 68, 69]. With regard to the degree of LDL-C and TC reduction, 15-year GHRT reduced the TC and LDL-C levels by 1.3 mmol/l (20%) and 1.6 mmol/l (32%), respectively [70].

Although LDL has long been identified as the most atherogenic type of lipoprotein, there is a growing evidence...
that in addition to the quantity of lipoproteins their quality is also associated with the risk and progression of coronary artery disease [71, 72]. Accordingly, the LDL size appears to be a considerable predictor of cardiovascular events with a predominance of small dense LDL (sdLDL) considered a novel cardiovascular risk factor [72]. Unfortunately, studies of LDL subfractions in GHD are still scarce and demonstrated inconsistent findings. An early study conducted on 30 patients demonstrated that GH-unreplaced patients had an excess of sdLDL compared to healthy controls [73]. Rizzo et al. conducted a small study (n = 14) and concluded that increased sdLDL might be common in GHD and that 4 months of GHRT did not affect LDL size [72]. On the contrary, Salmon et al. observed no significant difference in LDL subclasses between GHD patients and controls [74].

It should be emphasized that appropriate GH replacement is crucial in the management of dyslipidemia in AGHD. The cholesterol lowering effect of GHRT is proved to be at least additive to that of statins [75].

**Inflammatory markers**

Today C-reactive protein (CRP) is considered not only an inflammatory biomarker but also a useful prognostic tool in the evaluation of cardiovascular risk [76, 77].

CRP levels in GHD show approximately a fourfold to fivefold increase in both lean and obese individuals, which indicates the presence of a proinflammatory state [78]. In a randomized placebo-controlled study conducted by Sesmilo et al, the mean initial CRP level of the GHD study sample was similar to those observed in patients with a threefold increased risk for future myocardial infarction and a twofold risk for ischemic stroke in the Physicians’ Health Study [7, 76, 79]. In response to GHRT, the reduction in CRP levels was similar to those reported for pravastatin in the Cholesterol and Recurrent Events Study (CARE) [7, 79]. Importantly, the decrease of CRP levels cannot be fully attributed to weight loss or reduction of fat mass, because CRP reduction was also observed without any significant changes in body composition [6].

Some cytokines like tumor necrosis factor alpha (TNF-α) and interleukin-6 (IL-6) are also suggested to take part in the development of endothelial dysfunction and atherosclerosis in GHD [3]. Although studies on this topic often produced ambiguous results, several studies found negative correlation between GH and proinflammatory cytokines [80]. One study reported significantly elevated TNF-α levels in untreated adolescents with GHD compared to healthy controls. Another study also found higher baseline IL-6 levels in AGHD patients than in controls and demonstrated a significant decrease after 3-month GHRT, suggesting that GH might have an inhibitory effect on these cytokines [81]. Two studies recruiting children with GHD reported similarly elevated levels of TNF-α and reduction in response to GHRT [82, 83].

**Pregnancy-associated plasma protein-A (PAPP-A)**

Pregnancy-associated plasma protein-A (PAPP-A) is a high-molecular-weight metalloproteinase that can enhance local IGF-I bioavailability and possibly can alter a number of pathophysiological processes of atherogenesis [84]. Elevated PAPP-A levels were found in acute coronary syndrome and ischemic stroke, moreover PAPP-A is considered a marker for unstable atherogenic plaque [47, 85]. The relationship between PAPP-A levels and atherosclerosis is supported by preclinical studies where the loss of PAPP-A was found to promote plaque regression in mice [86]. A few studies investigating PAPP-A levels in AGHD detected elevated baseline PAPP-A levels which showed significant decrease after GHRT [85, 87].

**Markers of endothelial dysfunction and thrombogenesis**

Asymmetric dimethylarginine (ADMA) is an endogenous NO synthase inhibitor and is likely to participate in the development of endothelial dysfunction [88]. Supporting this theory, a meta-analysis (n = 19,842) revealed that patients in the top third of basal ADMA concentrations were at about 40% higher risk of cardiovascular disease compared to those in the bottom third [88]. Krzyzanowska et al. found elevated ADMA levels in hypopituitary patients, but regarding their ADMA levels no difference was found between GH deficient and GH sufficient patients [89]. Another study conducted on 31 adult GHD patients reported decreased ADMA levels after 6-month GHRT [90]. Interestingly, a significant decrease in ADMA levels were also reported in healthy subjects after 10 days of GH therapy [91].

Additionally, GHD is associated with alterations of coagulation and fibrinolysis [92]. Elevated levels of plasminogen activator inhibitor-1 (PAI-1) [92–94], fibrinogen [92, 94] and von Willebrand factor (vWF) [93] and a decrease in PAI-1 [94] in response to GHRT were reported in a relatively small number of studies. Higher E-Selectin [93, 95], P-selectin [96] and ICAM-1 [93] levels were also demonstrated in patients with GHD, and significant reduction in these adhesion molecules after 12 months of GHRT was also reported [96]. Furthermore, Cakir et al. observed a higher rate of Protein S deficiency in AGHD compared to general population and normalization with substitution [97]. In a small study (n = 21) Miljic et al. found a significant increase in prothrombin time (PT) and activated partial thromboplastin time (aPTT) after 12 months of GHRT [98].

Although, data obtained from these studies show some inconsistency, it is reasonable to state that GHD is associated
with a mild prothrombotic state which may act as an additional contributor to atherothrombotic events (Fig. 2).

**Oxidative stress**

Based on clinical and preclinical studies, oxidative stress (OS), defined by an imbalance between radical species and antioxidant defense, may have an important role in the development of metabolic alterations and atherosclerosis in GHD [99]. Accordingly, in an early study Evans et al. detected increased levels of lipid-derived free radicals and experienced improvement with 3-month GHRT [100]. On the contrary, another early study concluded that OS is not an important factor in the proatherogenic state in GHD [101]. More recently, Mancini et al. evaluated new parameters of OS as well as parameters of macromolecular oxidative damage and have found increased Total Antioxidant Capacity levels (as a consequence of greater antioxidant production to balance OS) in GHD reinforcing that OS is increased in patients with AGHD [8].

**Adipokines**

Besides regulating fat distribution, GH also modifies the endocrine function of the adipose tissue [102]. Adipokines participate in the regulation of energy balance, lipid and carbohydrate metabolism and inflammatory processes [102, 103]. It is also suggested that the GH/IGF-1 axis can influence the secretion of adipokines, which, in turn, can mediate metabolic effects of the GH/IGF-1 axis [102, 103]. The most frequently studied adipokines are leptin and adiponectin [104]. Leptin, the first adipokine to be discovered, shows a positive correlation with fat mass and is likely associated with OS and vascular damage [3, 105]. In GHD, some but not all studies reported higher levels of leptin [85, 106] and a decrease in response to GHRT [106, 107]. Adiponectin, the most abundant adipokine, is known for its antiatherogenic, insulin sensitizing and anti-inflammatory properties and has a key role in obesity-related diseases [108, 109]. Fukuda et al demonstrated significantly lower adiponectin levels in GHD when compared to acromegalic patients, but no differences were found compared with adiponectin levels of normal subjects [108]. Concerning the effect of GH substitution, elevated [110] and unchanged [111] adiponectin levels were also demonstrated in different trials. More recently, Wang et al. reported increased adipin levels in GHD patients compared to controls, and found a significant correlation with cardiometabolic risk factors [10]. Adipin is found to improve and maintain pancreatic β-cell function and to increase insulin secretion to glucose [112]. In obesity, higher adipin production is considered a form of compensatory mechanism for normalizing lipid and glucose metabolism [113]. This hypothesis may also explain the increased levels found in patients with AGHD.

**Vitamin D status**

Hypovitaminosis D represents an environmental risk factor for cardiovascular diseases and is associated with hypertension, dyslipidemia, endothelial dysfunction and impaired
insulin metabolism [114, 115]. Findings from the past decade suggest a functional relationship between the GH/IGF-1 axis and vitamin D, which then leads to the assumption that hypovitaminosis D may contribute to the higher cardiovascular risk profile in GHD [115]. One study conducted in 41 GH-naive patients revealed a higher prevalence of vitamin D deficiency compared to controls (51% vs.14.6%). The presence of hypovitaminosis D was also found to be the most powerful predictor of the prevalence of dyslipidemia and hypertension in GHD [115]. Another study with a larger sample (n = 129) found an even higher prevalence of hypovitaminosis (71.9%) in AGHD [116]. Interestingly, a subgroup of GH deficient patients fulfilling the criteria for MetS had a significantly lower mean 25(OH)D concentrations [116], which may indicate that lower mean 25(OH)D concentrations are associated with higher cardiovascular risk in patients with AGHD. Although favorable effects of vitamin D supplementation on the cardiovascular risk are not proven, vitamin D testing may help to identify patients with high adverse cardiovascular risk in AGHD [116].

**Visceral obesity in AGHD**

GH has important direct actions on adipocytes resulting in increased lipolysis and decreased lipogenesis. Moreover, GH also produces indirect actions influencing adipocyte growth and differentiation [117]. Obesity, which is a common finding in AGHD, is considered a consequence of blunted lipolysis leading to accumulation of mainly visceral fat [118].

Several mechanisms have been proposed to explain the link between visceral obesity and GHD. First, GHD is associated with a decreased hormone-sensitive lipase (HSL) activity, which has an essential role in the process of lipolysis [118]. Second, GH may influence the expression of CIDE-A (cell-death-inducing DFF45-like effector) protein, which has been associated with lipid accumulation and inhibition of lipolysis [118]. Third, GH regulates tissue glucocorticoid exposure by inhibiting the 11β-hydroxysteroid dehydrogenase type one (11β-HSD1) enzyme that interconverts inactive cortisone to active cortisol [119]. The inhibitory effect of GH on 11β-HSD1 leads to less cortisol production in the visceral adipose tissue, while GHD causes enhanced enzyme activity and visceral adiposity through local cortisol excess [120, 121].

According to early studies, fat mass is increased by 7% in GHD while lean body mass (LBM) decreased by 7–8% compared with predicted values [122]. Beneficial changes of GHRT on body composition are demonstrated in several studies [56, 123, 124]. One meta-analysis reported an increase in LBM of 2.7 kg and a reduction in fat mass of 3.1 kg in response to substitution [56]. Conversely, changes in body mass index and total body weight are observed in some but not all studies, and it seems that they do not necessarily change during GHRT [56, 123].

The effects of GHRT on body composition are considered dose-dependent with lower doses resulting in somewhat weaker effect on fat mass [56]. Different GH responsiveness in men and women is also documented and is explained by the effect of sex hormones. Testosterone has an enhancing effect on IGF-1 production while oral estrogen administration decreases hepatic IGF-1 synthesis; therefore, similar doses of GH cause less IGF-1 production and not so pronounced fat loss in women [124, 125]. The unfavorable effect of oral estrogen can be eliminated by administering transdermal or transvaginal estrogen instead. However, in a recent survey, only 10% of the endocrinologists considered switching from oral estrogen to a transdermal or transvaginal route [1].

Findings obtained from an RCT suggest that discontinuation may diminish the beneficial effects of long-term GHRT, and patients with a 4-month period of placebo treatment increased their waist circumference by 1.4 cm [126] which increases the cardiovascular risk by at least 2% [126, 127].

As for the duration of the improvements, in a 15-year observational study, lean soft tissue showed a sustained increase, and although, body fat returned to the baseline level, it was still well below the baseline when expressed as a percentage of total body weight [68].

**Insulin resistance and diabetes in treated and untreated patients with AGHD**

Insulin resistance and type 2 diabetes mellitus (T2DM) are well-established cardiovascular risk factors. Based on epidemiological evidence, a higher plasma glucose level not necessarily reaching the diabetic or even impaired glucose tolerance threshold also increases the cardiovascular risk [128].

Untreated patients with AGHD are found to be insulin resistant, which shows strong association with older age and percentage of fat mass [129]. Since GHRT leads to favorable changes of body composition, GH substitution would be expected to improve insulin sensitivity [130]. Conversely, studies in this field often reported unchanged or even deteriorating insulin sensitivity in response to GHRT [130]. Recently a meta-analysis demonstrated that short-term GHRT (6–12 months) resulted in deterioration of glucose metabolism including fasting insulin (FI), fasting plasma glucose (FPG), glycated hemoglobin (HgbA1C) and homeostasis model of assessment-insulin resistance (HOMA-IR), however, apart from FPG, negative effects of GHRT on these parameters are not observed in longer (> 12 months) GHRT [131].
Based on an international database which follows 6050 patients, the prevalence of diabetes mellitus is increased (SPR: 1.13) in untreated GHD, which is largely explained by the impaired body composition [132]. As far as treated GHD is concerned, another international follow up study found no evidence of increased prevalence of diabetes among patients receiving GHRT and concluded that higher susceptibility to diabetes is largely related to the increased prevalence of obesity and MetS in GHD rather than the GHRT itself [133].

In general, lower initial GH doses are recommended when GHD develops in a diabetic patient and antidiabetic therapy may need adjustment if GH replacement is started [22]. However, at present there are no specific recommendations regarding antidiabetic medications in AGHD. Interestingly, the dipeptidyl peptidase-4 inhibitor sitagliptin has been recently demonstrated to enhance endogenous GH and IGF-1 secretion in women [134] which may be beneficial in patients with coexisting diabetes and AGHD and is worth being examined in future research.

**Metabolic syndrome in patients with AGHD**

The prevalence of MetS is about 20–30% in the general population while it was found considerably higher in AGHD affecting about half of the patients [11, 135, 136]. In an analysis of 2479 patients with severe AGHD, the prevalence of MetS was 43.1% and 49.1% according to the definitions by NCEP-ATPIII and IDF respectively [11]. When comparing to patients with no MetS, patients with untreated AGHD and MetS also demonstrated higher prevalence rate for coronary and cerebrovascular morbidity [11].

It can be stated that GH substitution itself does not reduce the prevalence of Mets in patients with AGHD. In a recent analysis (n = 1449), 1-year GHRT did result in beneficial changes including a decrease in the percentage of patients with abnormal waist circumference, but the prevalence of MetS did not change [136]. Interestingly, patients without MetS proved to be much better GH responders and showed more favorable changes in the components of MetS than patients with MetS [136]. Another study demonstrated ongoing beneficial effects on lipid profile, but the prevalence of MetS increased significantly (57.1% vs. 32.7%) after 10 years of substitution and the increase was found higher than anticipated as a consequence of aging [70].

**Psychological well-being and cardiovascular health**

Impaired QoL, measured by the disease specific QoL-AGHDA and a series of other questionnaires, is a well-documented feature of AGHD [122, 137]. Memory, concentration, energy and vitality are affected most seriously in untreated hypopituitary adults, but depressed mood, social isolation and anxiety are also frequently reported [137, 138]. Timely and long-term GHRT is proved to be capable of improving QoL with older patients reaching the general population levels in 2 years [137].

From the clinical viewpoint, the positive change in the QoL is an important marker of the efficacy of hormone substitution, but it is generally not considered to be a possible contributor to cardiovascular health. As a matter of fact, negative psychological factors including anxiety and depression have a well-established role in the development and progression of cardiovascular diseases [139]. Anxiety disorder, which is found more frequent in GHD than in general population (38% vs. 13%) [140] is associated with an increased risk of cardiovascular mortality as well as specific cardiovascular diseases such as coronary heart disease, stroke and heart failure [141]. Social isolation, which normalizes early in response to GHRT [137], is associated with a 1.5-fold increased risk of coronary heart disease in adults and proved to worsen the prognosis when coexists with chronic conditions [142]. On the other hand, a growing body of evidence shows that positive psychological factors can affect cardiovascular health beneficially through healthier biological and behavioral processes such as healthier stress responses, better lifestyle choices and better compliance and adherence to medications [141].

In synthesis, improving QoL and psychological well-being not only improve patients functioning but may also have a favorable effect on the overall cardiovascular status and disease prognosis in AGHD.

**Differences of cardiovascular risk profile in subgroups of AGHD patients**

AGHD is considered a heterogenous condition in which the differences in the onset of the deficiency and the etiology not only influence the clinical presentation but also have an impact on the cardiovascular risk profile [2]. The marked differences in baseline characteristics and response to GHRT between CoGHD and AoGHD have long been recognized and documented. Basically, AoGHD is considered a metabolic disorder while CoGHD is a more complex syndrome including developmental as well as metabolic components [2, 143]. Patients with CoGHD are usually shorter, have lower initial BMI, waist-hip ratio (WHR), LBM and serum IGF-1 concentration as well as less disturbed baseline lipid profile including lower LDL-C and higher HDL-C levels [2, 144]. In a comparative, prospective study, initially, reduction in TC levels was observed only in patients with AoGHD, however, there were no differences in lipid concentrations between the two groups after 5 years of GH treatment indicating that lipid abnormalities of both CoGHD and AoGHD can be improved with long-term GHRT [144]. Besides the onset of the deficiency,
the influence of other hormone deficiencies and their replacement may also have an impact on the cardiovascular risk [145]. Accordingly, in a surveillance study, patients with multiple pituitary hormone deficiencies (MPHD) presented worse cardiometabolic risk profile than those with isolated GHD [145]. Certain etiologies like craniopharyngioma are also associated with more adverse cardiovascular risk profile [146]. Studies comparing craniopharyngioma patients with patients having non-functioning pituitary adenoma demonstrated that craniopharyngioma patients are more obese and dyslipidemic and less sensitive to the positive effects of GHRT on fat mass and lipid profile which, at least partly explain the higher mortality rate observed in this subgroup [146–148].

Cardiometabolic risk profile in patients with biochemical GHD

In the past decades, a few clinical conditions were identified to be associated with reduced growth hormone secretion, which do not meet the standard criteria for true GHD. This alteration in GH secretion, often referred to as biochemical or functional GHD, has been reported in a subgroup of patients with human immunodeficiency virus (HIV) infection as well as in patients with chronic heart failure (CHF) and are suggested to have negative impact on disease progression [149–151].

Lipodystrophy is a common endocrine abnormality in HIV-infected patients receiving highly active antiretroviral therapy (HAART) [150]. HIV-related lipodystrophy is characterized by an increase of visceral fat mass which, given the well-known effects of GHD on fat distribution, directed the attention towards pituitary GH secretion as a potential contributor to the development of lipodystrophy [150]. Eventually, biochemical GHD was found to be common in HIV infection, affecting about one-third of the patients [150]. Although, the significance and mechanism of impaired GH secretion in HIV is far from clear, patients with biochemical GHD demonstrate alterations that are frequently observed in true GHD, which supports the presence of a clinically significant GH deficiency [150, 152]. Cardiovascular diseases are leading causes of death in patients with HIV infection [153]. Risk factors in HIV probably involve traditional cardiovascular risk factors as well as factors associated with the antiretroviral therapy [153]; however, biochemical GHD characterized by increased visceral adiposity, dyslipidemia, inflammation and altered glucose metabolism may also contribute to the higher cardiovascular mortality among these patients [152].

CHF is often associated with multiple hormonal deficiencies which identifies a subgroup of patients with worse prognosis and higher mortality [154]. GHD, which affects approximately 30% of these patients, is considered a key component among anabolic hormone deficiencies [151, 155]. The presence of GHD in CHF is associated with worse clinical status, reduced QoL, worse depression scores, LV remodeling, lower physical performance, increased NT-proBNP levels and higher all-cause mortality [151]. Circulating IGF-1 levels in CHF can be lower, unchanged or higher compared with healthy subjects; however, low IGF-1 shows correlation with systolic dysfunction, skeletal muscle performance and neurohormonal and cytokine activation [156, 157]. A number of studies have attempted to evaluate the effects of growth hormone therapy in CHF; unfortunately many of them provided conflicting results probably due to differences in the administered treatment and inclusion of patients regardless of their GH/IGF-1 profile [156]. Cittadini et al. conducted a randomized, single-blinded, controlled trial on 158 patients with CHF (NYHA II-IV) and found significant improvement in exercise capacity, QoL and LV structure and function in patients receiving GH replacement [154]. When they assessed the patients in a 4-year follow-up study, they found that long-term GH replacement in patients with CHF resulted in increased EF, decreased LV end-systolic and end-diastolic volume, reduced wall stress as well as reduced hospitalization rate due to CHF worsening [158].

Cardiovascular evaluation in AGHD

Adults with GHD have an increased risk of cardiovascular morbidity and mortality; therefore, it is essential for these patients to undergo regular evaluation of cardiovascular parameters. Based on the recent guideline, parameters that are considered to be monitored at 6–12-month intervals include blood pressure and heart rate while more thorough evaluation involving electrocardiography, echocardiography and carotid echo-Doppler examination can be performed if clinically indicated [22]. In the absence of disease-specific guidelines detailing how to assess the cardiovascular status of these patients, we generally recommend close follow-up of the cardiovascular status as well as low threshold for a more detailed evaluation.

Echocardiography

Due to its widespread availability, echocardiography is commonly used for the diagnosis and management of cardiovascular diseases [159]. Echocardiographic findings in AGHD may involve reduced LV mass especially in young patients and impaired LV function [45]. Several studies demonstrated positive effects of GHRT on LV mass [45], IVS [45, 53] and LVPW [45, 53] probably resulting from the hypertrophic effect of GH [76] and contributing to the improved cardiac performance in treated patients. Besides cardiac MRI, echocardiography is considered the best modality to assess LV
mass [160] with several methods available for the effective calculation including M-mode echocardiography, 2DE and 3DE [159]. LV mass is generally presented as LV mass index (LVMI) where LV mass is indexed to height, weight or body surface area allowing it to compare different patients with different stature [159]. Based on the recommendations of the American Society of Echocardiography (ASE), 2DE is considered an advisable method for follow-up of changes of LVMI in an individual patient [159]. Ejection fraction (EF) is the most widely-used and accepted echocardiographic parameter of the LV systolic function [161]. In AGHD a substantial number of studies employing echocardiography and the highly sensitive radionuclide angiography found reduced EF, which improved with GHRT [46, 53, 162]. At present, the biplane method of disks (modified Simpson’s rule) is the recommended 2 DE method to assess LVEF with EFs lower than 52% for men and 54% for women considered indicative of LV systolic dysfunction [159, 161].

Because of the growing need for more reliable measures of systolic function, new techniques including 3D and STE are expected to become widely available in the near future [161]. STE allows angle-independent evaluation of myocardial function and it also has a potential to detect subclinical systolic dysfunction not evident by LVEF assessment [163, 164]. To the best of our knowledge, there was only one study in which both conventional 2DE and 2D STE were used to evaluate the cardiac function in AGHD. In this study (n = 52) more than half of the patients had an LVEF within normal ranges when assessed with conventional 2DE [9]. In contrast, 2D STE revealed decreased global longitudinal (GLS) and circumferential (GCS) strain in all patients with GHD [9]. It is widely-known that patients with reduced LVEF pose a high risk of all-cause mortality but this is not applicable to patients with an LVEF higher than 40–45% [161, 165]. Conversely, GLS, the most commonly used strain-based measure of global systolic function, provides prognostic information when EF is normal or near-normal [159, 165]. Accordingly, a meta-analysis involving 5721 patients confirmed that GLS impairment is superior to LVEF in the prediction of death and major cardiac events [165].

**Cardiac magnetic resonance imaging (CMRI)**

CMRI is now considered a reference standard for the evaluation of cardiac function and morphology because of its high accuracy and independence of acoustic windows. In the clinical setting, CMRI can be utilized to evaluate several parameters including tissue composition, wall motion, blood flow and metabolism [166]. From another aspects, due to its high reproducibility, CMRI allows a substantial reduction in patient numbers compared to conventional echocardiography [167] making it a reasonable modality in clinical trials with rare diseases like AGHD, which often face difficulties with small sample sizes. Studies employing CMRI in AGHD confirmed the previously reported morphological changes and reported reduced LVMI in untreated patients [49, 51] which increased in response to GHRT [48, 49]. One study also reported reduced aortic area in untreated patient [49]. An evaluation of gadolinium enhancement, a useful tool for tissue characterization, was performed in two studies in AGHD. The basis for the examination is that several minutes after its administration, gadolinium-based contrast medium shows a greater distribution volume in necrotic or fibrotic myocardium than in viable myocardium. This is commonly referred to as late gadolinium enhancement or delayed enhancement [166, 168]. In AGHD, late enhancement was detected only in patients with a known history of ischemic heart disease, making it clear that cardiac morpho-functional alterations in AGHD are not related to fibrosis or inflammatory degeneration [49, 51].

**Carotid ultrasonography**

Ultrasound examination of the carotid arteries allows detection and characterization of carotid plaques and measurement of CIMT which are particularly important in the cardiovascular risk assessment [169–171]. Increased CIMT, defined as IMT higher than 0.9 mm, is considered an early sign of atherosclerosis and is associated with increased risk of stroke and myocardial infarction [172]. Plaque is generally defined as a focal thickening that is at least 50% greater than the surrounding sites or as a focal region with CIMT measurement ≥ 1.5 mm that protrudes into the arterial lumen [173, 174]. Based on the current recommendations, examination of both IMT and plaque area is of greater value in the estimation of cardiovascular risk, than examining CIMT alone [174]. In AGHD not all but several studies demonstrated increased CIMT and restoration after hormone substitution [58–60]. In one study, ultrasonic imaging of both the carotid and femoral arteries revealed that GH deficient patients not only had increased CIMT, but the percentage of individual arteries with a plaque was also higher in them than in healthy controls [58]. From the therapeutic viewpoint, it is important to emphasize that arterial plaque burden should be considered as a risk modifier and significant plaque on carotid ultrasonography automatically places the patient into the very high risk category where active management of all risk factors should be warranted [169].

**Electrocardiography**

Electrocardiography is a non-invasive and unexpensive test, which is universally incorporated in the routine cardiological diagnostics. It is a safe and easily available modality for cardiovascular risk stratification [175]. However, according to the current guidelines, standard 12-lead electrocardiogram
does not have an established role in the cardiovascular risk assessment [176]. In fact, the US Preventive Services Task Force (USPSTF) does not recommend employing resting or exercise ECG to prevent cardiovascular events in asymptomatic adults [176, 177].

GHD is known to influence sympathetic outflow and have an unfavorable effect on the structure and function of the cardiovascular system [23], but a little is known about how GHD and GHRT affect arrhythmogenesis. Only a few studies have tested the hypothesis that higher cardiovascular mortality in GHD might be associated with cardiac autonomic dysregulation. Heart rate variability (HRV) assessment is an accepted non-invasive method for assessing the cardiac autonomic tone [178]. Measurement of HRV can be classified into time-domain variables usually derived from 24-h ECG recordings and frequency-domain variables which are derived from power spectral analysis [178]. Leong et al. performed a small study (n = 14) using frequency-domain parameters and detected decreased sympathetic tone in untreated GH deficient adults [179]. Previous studies linked depressed sympathovagal tone to higher mortality in post-myocardial patients and in patients with congestive heart failure [180]. In another study, Leong et al. also evaluated the effect of 6 months GHRT on HRV and found similar cardiac autonomic tone in treated GHD patients and in healthy controls suggesting that cardiac autonomic dysfunction could be corrected by GH replacement [180]. Studies using time-domain variables also found decreased sympathetic tone in adults with untreated GHD, which increased significantly with GHRT [178, 181]. On the contrary, Boschetti et al. did not detect sympathovagal imbalance in untreated patients, although, patients having GHD for more than 2 years were not included in the study [182]. Consequently, it cannot be excluded that patients untreated for more than 2 years may exhibit cardiac autonomic dysfunction [182].

In the past two decades, different electrocardiographic markers including the Tp-e interval (distance between the peak and end points of T-wave) and Tp-e/QT ratio (arrhythmogenic index) have been identified as predictors of ventricular arrhythmias [183, 184]. Tp-e interval and Tp-e/QT ratios have been investigated in many conditions affecting the cardiovascular system including diabetes and hypothyroidism and have been found indicative of higher risk for ventricular arrhythmias [184, 185]. Despite the well-documented cardiovascular involvement, clinical electrocardiographic studies are still scarce in AGHD, and the above-mentioned electrocardiographic markers of arrhythmias have not been investigated.

**Conclusions**

AGHD is a clinical entity characterized by numerous metabolic abnormalities and increased cardiovascular morbidity and mortality. Adequate GH replacement produces favorable changes in body composition, lipid profile and QoL, affects cardiac structure and function positively and indirectly reduces mortality in hypopituitary patients. Nevertheless, it is also evident that GHRT in itself is not capable of eliminating all cardiometabolic abnormalities observed in AGHD; therefore, active screening and treatment of cardiovascular risk factors should be integrated in the routine management. Greater awareness of the advantages of growth hormone substitution among patients and healthcare professionals would be necessary to improve adherence and outcome in AGHD.

**Author contributions** All authors contributed to the article and approved the submitted version.

**Funding** Open access funding provided by University of Debrecen. The work was supported by the GINOP-2.3.2-15-2016-00005.

**Data availability** Not applicable.

**Code availability** Not applicable.

**Declarations**

**Conflict of interest** The authors have no conflicts of interest to declare that are relevant to the content of this article.

**Research involving human and animal rights** All procedures performed in studies involving human participants and animals were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This is a review paper; therefore, no informed consent was used, a separate ethic review and permission of a local committee was not necessary.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
References

1. Martel-Duguech LM, Jorgensen JOL, Korbonits M, Johannsson G, Webb SM, Amadou F et al (2020) ESE audit on management of adult growth hormone deficiency in clinical practice. Eur J Endocrinol. https://doi.org/10.1530/EJE-20-1180

2. Attanasio AF, Lamberts SW, Matranga AM, Birkett MA, Bates PC, Valk NK et al (1997) Adult growth hormone (GH)-deficient patients demonstrate heterogeneity between childhood onset and adult onset before and during human GH treatment. Adult Growth Hormone Deficiency Study Group. J Clin Endocrinol Metab 82:82–88. https://doi.org/10.1210/jcem.82.1.3543

3. Gazzaruso C, Gola M, Karamonius I, Giubini R, Giustina A (2014) Cardiovascular risk in adult patients with growth hormone (GH) deficiency and following substitution with GH—an update. J Clin Endocrinol Metab 99:18–29. https://doi.org/10.1210/jc.2013-2394

4. van Bunderen CC, Olsson DS (2021) Growth hormone deficiency and replacement therapy in adults: impact on survival. Rev Endocr Metab Disord 22:225–133. https://doi.org/10.1007/s11154-020-09599-w

5. Sherlock M, Ayuk J, Tomlinson JW, Toogood AA, Aragon-Alonso A, Sheppard MC et al (2010) Mortality in patients with pituitary disease. Endocr Rev 31:301–342. https://doi.org/10.1210/er.2009-0033

6. Deepak D, Daouci C, Javadpour M, Clark D, Perry Y, Pinkney J et al (2010) The influence of growth hormone replacement on peripheral inflammatory and cardiovascular risk markers in adults with severe growth hormone deficiency. Growth Horm IGF Res Off J Growth Horm Res Soc Int IGF Res Soc 20:220–225. https://doi.org/10.1016/j.gihor.2010.02.002

7. Sesmilo G, Biller BM, Llevadot J, Hayden D, Hanson G, Rifai N et al (2000) Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency. A randomized, controlled clinical trial. Ann Intern Med 133:111–122. https://doi.org/10.7326/0003-4819-133-2-200007180-00010

8. Mancini A, Bruno C, Vergani E, Guidi F, Angelini F, Meucci E et al (2020) Evaluation of oxidative stress effects on different macromolecules in adult growth hormone deficiency. PLoS ONE 15:e0236357. https://doi.org/10.1371/journal.pone.0236357

9. Mihaia S, Mincu RI, Râncu RL, Del Popolo MP, Râncu M, Magda SL et al (2015) Growth hormone deficiency in adults impacts left ventricular mechanics: a two-dimensional speckle-tracking study. Can J Cardiol 31:752–759. https://doi.org/10.1016/j.cjca.2015.01.008

10. Wang Y, Zheng X, Xie X, Qian W, Zhang L, Ren W (2019) Correlation of increased serum adipin with increased cardiovascular risks in adult patients with growth hormone deficiency. Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol 25:446–453. https://doi.org/10.4188/EP-2018-0541

11. Verhelst J, Mattsson AF, Lugan A, Thunander M, Göth ML, Kołtowska-Häggström M et al (2011) Prevalence and characteristics of the metabolic syndrome in 2479 hypopituitary patients with adult-onset GH deficiency before GH replacement: a KIMS analysis. Eur J Endocrinol 165:881–889. https://doi.org/10.1530/EJE-11-0599

12. Gaillard RC, Mattsson AF, Akerblad A-C, Bengtsson B-Å, Cara J, Feldt-Rasmussen U et al (2012) Overall and cause-specific mortality in GH-deficient adults on GH replacement. Eur J Endocrinol 166:1069–1077. https://doi.org/10.1530/EJE-11-1028

13. Yuen KCJ, Llahana S, Miller BS (2019) Adult growth hormone deficiency: clinical advances and approaches to improve adherence. Expert Rev Endocrinol Metab 14:419–436. https://doi.org/10.1080/17446651.2019.1689119

14. Melmed S (2019) Pathogenesis and diagnosis of growth hormone deficiency in adults. N Engl J Med 380:2551–2562. https://doi.org/10.1056/NEJMra1817346

15. Pekic S, Popovic V (2017) Diagnosis of endocrine disease: expanding the cause of hypopituitarism. Eur J Endocrinol 176:R269–R282. https://doi.org/10.1530/EJE-16-1065

16. Webb S, Strasburger C, Mo D, Hartman M, Melmed S, Jung H et al (2008) Changing patterns of the adult growth hormone deficiency diagnosis documented in a decade-long global surveillance database. J Clin Endocrinol Metab 94:392–399. https://doi.org/10.1210/jc.2008-0713

17. Tanriverdi F, Kellestimur F (2017) Classical and non-classical causes of GH deficiency in adults. Best Pract Res Clin Endocrinol Metab 31:3–11. https://doi.org/10.1016/j.beem.2017.02.001

18. Brabant G, Poll EM, Jönsson P, Polydorou D, Kreitsschmann-Andermahr I (2009) Etiology, baseline characteristics, and biochemical diagnosis of GH deficiency in the adult: are there regional variations? Eur J Endocrinol 161(Suppl 1):S25–31. https://doi.org/10.1530/EJE-09-0273

19. Prete A, Salvadori R (2018) Management of adults with childhood-onset growth hormone deficiency. In: Radovick S, Misra M (eds) Pediatric endocrinology: a practical clinical guide. Springer, Cham, pp 145–174. https://doi.org/10.1007/978-3-319-75782-9_7

20. Lissett CA, Shalet SM (2002) Childhood-onset growth hormone (GH) deficiency in adult life. Best Pract Res Clin Endocrinol Metab 16:209–224. https://doi.org/10.1053/beem.2002.0196

21. Sklar CA, Antal Z, Chemaitilly W, Cohen LE, Follin C, Meacham LR et al (2018) Hypothalamic-pituitary and growth disorders in survivors of childhood cancer: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 103:2761–2784. https://doi.org/10.1210/jc.2018-01175

22. Yuen KCJ, Biller BMK, Radovick S, Carmichael JD, Jasim S, Pantalone KM et al (2019) American Association of Clinical Endocrinologists and American college of endocrinology guidelines for management of growth hormone deficiency in adults and patients transitioning from pediatric to adult care. Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol 25:1191–1232. https://doi.org/10.4158/CL-2019-0405

23. Isgaard J, Arcopinto M, Karason K, Cittadini A (2015) GH and the cardiovascular system: an update on a topic at heart. Endocrine 48:25–35. https://doi.org/10.1007/s12020-014-0327-6

24. Castellano G, Affuso F, Conza PD, Fazio S (2009) The GH/IGF-I axis and heart failure. Curr Cardiovasc Rev 5:203–215. https://doi.org/10.2174/157343030978970306

25. Lombardi G, Di Somma C, Grasso LFS, Savanelli MC, Colao A, Pivonello R (2012) The cardiovascular system in growth hormone excess and growth hormone deficiency. J Endocrinol Invest 35:1021–1029. https://doi.org/10.3275/8717

26. Müntzel T, Feil R, Mülsch A, Lohmann SM, Hofmann F, Walter U (2003) Physiology and pathophysiology of vascular signaling controlled by cyclic guanosine 3′,5′-cyclic monophosphate-dependent protein kinase. Circulation 108:2172–2183. https://doi.org/10.1161/01.CIR.0000094403.78467.C3

27. Levine AB, Punihalde D, Levine TB (2012) Characterization of the role of nitric oxide and its clinical applications. Cardiology 122:55–68. https://doi.org/10.1159/000338150

28. Standley PR, Obards TJ, Martina CL (1999) Cyclic stretch regulates autocrine IGF-I in vascular smooth muscle cells: implications in vascular hyperplasia. Am J Physiol 276:E697–705. https://doi.org/10.1152/ajpendo.1999.276.4.E697

29. Tivesten A, Barlind A, Caidahl K, Klingland N, Cittadini A, Ohlsson C et al (2004) Growth hormone-induced blood pressure decrease is associated with increased mRNA levels of the...
vascular smooth muscle KATP channel. J Endocrinol 183:195–202. https://doi.org/10.1677/joe.1.05726
30. Sverrisdóttir YB, Elam M, Caidahl K, Söderling A-S, Herlitz H, Johannsson G (2003) The effect of growth hormone (GH) replacement therapy on sympathetic nerve hyperactivity in hypopituitary adults: a double-blind, placebo-controlled, crossover, short-term trial followed by long-term open GH replacement in hypopituitary adults. J Hypertens 21:1905–1914. https://doi.org/10.1097/01.hjh.0000084757.37215.55
31. Strazhko IDS, Tkacheva ON, Akasheva DU, Dudinskaya EN, Plokhova EV, Pykhchina VS et al (2017) Growth hormone, insulin-like growth factor-1, insulin resistance, and leukocyte telomere length as determinants of arterial aging in subjects free of cardiovascular diseases. Front Genet 8:198. https://doi.org/10.3389/fgen.2017.00198
32. Ito H, Hiroe M, Hirata Y, Tsujino M, Adachi S, Shichiri M et al (1993) Insulin-like growth factor-I induces hypertrophy with enhanced expression of muscle specific genes in cultured rat cardiomyocytes. Circulation 87:1715–1721. https://doi.org/10.1161/01.cir.87.5.1715
33. Fazio S, Cittadini A, Sabatini D, Merola B, Colao A, Biondi B et al (1997) Growth hormone and heart performance. A novel mechanism of cardiac wall stress regulation in humans. Eur Heart J 18:340–347. https://doi.org/10.1093/oxfordjournals.eurheart.a013527
34. Cittadini A, Ishiguro Y, Strömer H, Spindler M, Moses AC, Clark R et al (1998) Insulin-like growth factor-1 but not growth hormone augments mammalian myocardial contractility by sensitizing the myofilament to Ca²⁺ through a wortmannin-sensitive pathway: studies in rat and ferret isolated muscles. Circ Res 83:50–59. https://doi.org/10.1161/01.res.83.1.50
35. Freesten NS, Ribaric S, Mason WT (1996) The effect of insulin-like growth factor-1 on adult rat cardiac contractility. Mol Cell Biochem 163–164:223–229. https://doi.org/10.1007/BF00408662
36. Tajima M, Weinberg EO, Bartunek J, Jin H, Yang R, Paoni NF et al (1999) Treatment with growth hormone enhances contractile reserve and intracellular calcium transients in myocytes from rats with postinfarction heart failure. Circulation 99:127–134. https://doi.org/10.1161/01.cir.99.1.127
37. Colao A, Marzullo P, Lombardi G (2001) Growth hormone and the heart. Clin Endocrinol (Oxf) 54:137–154. https://doi.org/10.1046/j.1365-2265.2001.01218.x
38. Cittadini A, Cuocolo A, Merola B, Fazio S, Sabatini D, Nicolai E et al (1994) Impaired cardiac performance in GH-deficient adults and its improvement after GH replacement. Am J Physiol E223:E219-225. https://doi.org/10.1152/ajpendo.1994.267.2.E219
39. Longobardi S, Cuocolo A, Merola B, Di Rella F, Colao A, Nicolai E et al (1998) Left ventricular function in young adults with childhood and adulthood onset growth hormone deficiency. Clin Endocrinol (Oxf) 48:137–143. https://doi.org/10.1046/j.1365-2265.1998.00281.x
40. Amato G, Carella C, Fazio S, La Montagna G, Cittadini A, Sabatini D et al (1993) Body composition, bone metabolism, and heart structure and function in growth hormone (GH)-deficient adults before and after GH replacement therapy at low doses. J Clin Endocrinol Metab 77:1671–1676. https://doi.org/10.1210/jcem.77.6.8263158
41. Caidahl K, Edén S, Bengtsson BA (1994) Cardiovascular and renal effects of growth hormone. Clin Endocrinol (Oxf) 40:393–400. https://doi.org/10.1111/j.1365-2265.1994.tb03937.x
42. Thuesen L, Jørgensen JO, Müller JR, Kristensen BO, Skakkebaek NE, Vahl N et al (1994) Short and long-term cardiovascular effects of growth hormone therapy in growth hormone deficient adults. Clin Endocrinol (Oxf) 41:615–620. https://doi.org/10.1111/j.1365-2265.1994.tb01827.x
43. Valsecchi R, Gaddi O, Zini M, Iavicoli M, Mellino U, Portioli I (1995) Cardiac performance and mass in adults with hypopituitarism: effects of one year of growth hormone treatment. J Clin Endocrinol Metab 80:659–666. https://doi.org/10.1210/jcem.80.2.7852533
44. ter Maaten JC, de Boer H, Kamp O, Stuurman L, van der Veen EA (1999) Long-term effects of growth hormone (GH) replacement in men with childhood-onset GH deficiency: 1. J Clin Endocrinol Metab 84:2373–2380. https://doi.org/10.1210/jcem.84.7.5851
45. Mäson P, Chanson P (2003) Cardiac effects of growth hormone in adults with growth hormone deficiency: a meta-analysis. Circulation 108:2648–2652. https://doi.org/10.1161/01.CIR.0000010720.01867.1D
46. Colao A, Cuocolo A, Di Somma C, Cerbone G, Morte AM, Pivonello R et al (2000) Does the age of onset of growth hormone deficiency affect cardiac performance? A radionuclide angiography study. Clin Endocrinol (Oxf) 52:447–455. https://doi. org/10.1046/j.1365-2265.2000.00972.x
47. Di Somma C, Scaranò E, Savastano S, Savanelli MC, Pivonello R, Colao A (2017) Cardiovascular alterations in adult GH deficiency. Best Pract Res Clin Endocrinol Metab 31:25–34. https://doi.org/10.1016/j.beem.2017.03.005
48. Andreassen M, Faber J, Kjaer A, Petersen CL, Kristensen LØ (2011) Cardiac function in growth hormone deficient patients before and after 1 year with replacement therapy: a magnetic resonance imaging study, Pituitary 14:1–10. https://doi.org/10.1007/s11102-010-0250-7
49. Thomas JDI, Dattani A, Zemrak T, Burchell A, Akker S, Gurnell M et al (2016) Characterisation of myocardial structure and function in adult-onset growth hormone deficiency using cardiac magnetic resonance. Endocrine 54:778–787. https://doi.org/10.1007/s12020-016-1067-6
50. Gonzalez S, Windram JD, Sathyapalan T, Javed Z, Clark AL, Atkin SL (2017) Effects of human recombinant growth hormone on exercise capacity, cardiac structure, and cardiac function in patients with adult-onset growth hormone deficiency. J Int Med Res 45:1708–1719. https://doi.org/10.1177/030605171772798
51. De Cobelli F, Rossi A, Esposito A, Canu T, Manzoni G, Del Maschio A et al (2019) Short-term evaluation of cardiac morphology, function, metabolism and structure following diagnosis of adult-onset growth hormone deficiency. Growth Horm IGF Res Off J Growth Horm Res Soc Int IGF Res Soc 46–47:50–54. https://doi.org/10.1016/j.ghir.2019.06.003
52. Boscetti M, Agosti S, Albanese V, Casalino L, Tetti C, Bezante GP et al (2017) One-year GH replacement therapy reduces early cardiac target organ damage (TOD) in adult GHD patients. Endocrine 55:573–581. https://doi.org/10.1007/s12020-016-0951-4
53. Zhang S, Li Z, Lv Y, Sun L, Xiao X, Gang X et al (2020) Cardiovascular effects of growth hormone (GH) treatment on GH-deficient adults: a meta-analysis update. Pituitary 23:467–475. https://doi.org/10.1007/s11102-020-01036-0
54. Sanmarti A, Lucas A, Hawkins F, Webb SM, Ullied A (1999) Observational study in adult hypopituitary patients with untreated growth hormone deficiency (ODA study). Socio-economic impact and health status. Collaborative ODA (Observational GH Deficiency in Adults) Group. Eur J Endocrinol 141:481–489. https://doi.org/10.1530/eje.0.1410481
55. Conceição FL, de Rooij Mansur VA, Brasil RRLO, Vaisman M (2002) Ambulatory monitoring of blood pressure in growth hormone-deficient adults. Blood Press Monit 7:89–94. https://doi.org/10.1097/00126097-200204000-00001
56. Maison P, Griffin S, Nicole-Begla M, Haddad N, Balkau B, Chansonn P et al (2004) Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults: a metaanalysis of blinded, randomized, placebo-controlled trials. J Clin Endocrinol Metab 89:2192–2199. https://doi.org/10.1210/jc.2003-030840

57. Ahmad AM, Hopkins MT, Weston PJ, Fraser WD, Vora JP (2002) Effects of GH replacement on 24-h ambulatory blood pressure and its circadian rhythm in adult GH deficiency. Clin Endocrinol (Oxf) 56:431–437. https://doi.org/10.1046/j.1365-2265.2002.01491.x

58. Markusis V, Beshyah SA, Fisher C, Sharp P, Nicolaides AN, Johnston DG (1992) Detection of premature atherosclerosis by high-resolution ultrasonography in symptom-free hypopituitary adults. Lancet Lond Engl 340:1188–1192. https://doi.org/10.1016/S0140-6736(92)92892-j

59. Lekakis JP, Papamichael CM, Cinponeriu AT, Stamatelopoulos KS, Papaioannou TG, Kanakakis J et al (2000) Atherosclerotic changes of extracoronary arteries are associated with the extent of coronary artery disease. Am J Cardiol 85:949–952. https://doi.org/10.1016/S0002-9149(99)00907-8

60. Borson-Chazot F, Serusclat A, Kalfallah Y, Ducottet X, Sassolas G, Bernard S et al (1999) Decrease in carotid intima-media thickness after one year growth hormone (GH) treatment in adults with GH deficiency1. J Clin Endocrinol Metab 84:1329–1333. https://doi.org/10.1210/jcem.84.4.5359

61. Pfeifer M, Verhovec R, Zizek B, Frezelj J, Poredos P, Clayton RN (1999) Growth hormone (GH) treatment reverses early atherosclerotic changes in GH-deficient adults1. J Clin Endocrinol Metab 84:453–457. https://doi.org/10.1210/jcem.84.2.5456

62. Gibney J, Wallace JD, Spinks T, Schnorr L, Ranicar A, Cuneo RC et al (1999) The effects of 10 years of recombinant human growth hormone (GH) in adult GH-deficient patients. J Clin Endocrinol Metab 84:2596–2602. https://doi.org/10.1210/jcem.84.8.5916

63. Lehmann ED, Hopkins KD, Weissberger AJ, Gosling RG, Sönksen PH (1993) Aortic distensibility in growth hormone deficient adults. Lancet Lond Engl 341:309. https://doi.org/10.1016/0140-6736(93)92664-f

64. Lanes R, Soros A, Flores K, Gunczler P, Carrillo E, Bandel J (2005) Endothelial function, carotid artery intima-media thickness, epicardial adipose tissue, and left ventricular mass and function in growth hormone-deficient adolescents: apparent effects of growth hormone treatment on these parameters. J Clin Endocrinol Metab 90:3978–3982. https://doi.org/10.1210/jcem.2005-0091

65. Abdu TA, Neary R, Elhadd TA, Akber M, Clayton RN (2001) Coronary risk in growth hormone deficient hypopituitary adults: increased predicted risk is due largely to lipid profile abnormalities. Clin Endocrinol (Oxf) 55:209–216. https://doi.org/10.1046/j.1365-2265.2001.01320.x

66. Giagulli VA, Castellana M, Perrone R, Guastamacchia E, Nicolaides AN, Johnston DG (2017) GH supplementation effects on body composition, bone mass, and metabolic indices. J Clin Endocrinol Metab 86:4657–4665. https://doi.org/10.1210/jcem.86.10.7887

67. Florakis D, Hung V, Kaltzas G, Coyte D, Jenkins PJ, Chew SL et al (2000) Sustained reduction in circulating cholesterol in adult hypopituitary patients given low dose titrated growth hormone replacement therapy: a two year study. Clin Endocrinol (Oxf) 53:453–459. https://doi.org/10.1046/j.1365-2265.2000.01108.x

68. Elbornsson M, Götherström G, Bosaeus I, Bengtsson B-Å, Johansson G, Svensson J (2013) Fifteen years of GH replacement improves body composition and cardiovascular risk factors. Eur J Endocrinol 168:745–753. https://doi.org/10.1530/EJE-12-1083

69. Götherström G, Svensson J, Koranyi J, Alpsten M, Bosaeus I, Bengtsson B et al (2001) A prospective study of 5 years of GH replacement therapy in GH-deficient adults: sustained effects on body composition, bone mass, and metabolic indices. J Clin Endocrinol Metab 86:4657–4665. https://doi.org/10.1210/jcem.86.10.7887

70. Claessen KJMA, Appelman-Dijkstra NM, Adoptie DMMM, Roelfsema F, Smit JWA, Biermasz NR et al (2013) Metabolic profile in growth hormone-deficient (GHD) adults after long-term recombinant human growth hormone (rhGH) therapy. J Clin Endocrinol Metab 98:352–361. https://doi.org/10.1210/jc.2012-2940

71. Hirayama S, Miida T (2012) Small dense LDL: an emerging risk factor for cardiovascular disease. Clin Chim Acta 414:215–224. https://doi.org/10.1016/j.cca.2012.09.010

72. Rizzo M, Trepp R, Berneis K, Christ ER (2007) Atherogenic lipoprotein phenotype and low-density lipoprotein size and subclasses in patients with growth hormone deficiency before and after short-term replacement therapy. Eur J Endocrinol 156:361–367. https://doi.org/10.1530/EJE-06-0652

73. O’Neill D, Hew FL, Sikaris K, Ward G, Alford F, Best JD (1996) Low density lipoprotein particle size in hypopituitary adults receiving conventional hormone replacement therapy. J Clin Endocrinol Metab 81:2448–2454. https://doi.org/10.1210/jcem.81.7.8675559

74. Salman S, Uzum AK, Telci A, Alagol F, Ozbay NC (2012) Serum adipokines and low density lipoprotein subfraction profile in hypopituitary patients with growth hormone deficiency. Pituitary 15:386–392. https://doi.org/10.1007/s11120-011-0332-1

75. Monsson JP, Jönsson P, Koltowska-Hägström M, Kourides I (2007) Growth hormone (GH) replacement decreases serum total and LDL-cholesterol in hypopituitary patients on maintenance HMG CoA reductase inhibitor (statin) therapy. Clin Endocrinol (Oxf) 67:623–628. https://doi.org/10.1111/j.1365-2265.2007.02935.x

76. Gola M, Bonadonna S, Doga M, Giustina A (2005) Clinical review: growth hormone and cardiovascular risk factors. J Clin Endocrinol Metab 90:1864–1870. https://doi.org/10.1210/jcem.2004-0545

77. Libby P (2012) Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol 32:2045–2051. https://doi.org/10.1161/ATVBAHA.110.179705

78. Ukoçoğlu Z et al (2008) Adipokine protein expression pattern in growth hormone deficiency predisposes to the increased fat cell size and the whole body metabolic derangements. J Clin Endocrinol Metab 93:2255–2262. https://doi.org/10.1210/jc.2007-2188

79. Rickert PM, Riffai N, Pfeifer MA, Sacks F, Braunwald E (1999) Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 100:230–235. https://doi.org/10.1161/01.cir.100.3.230

80. Szalecki M, Malinowska A, Prokop-Piotrowska M, Janas R (2018) Interactions between the growth hormone and cytokines—a review. Adv Med Sci 63:285–289. https://doi.org/10.1016/j.adms.2018.03.001

81. Serri O, St-Jacques P, Sartippour M, Renier G (1999) Alterations of monocyte function in patients with growth hormone (GH) deficiency: effect of substitutive GH therapy. J Clin Endocrinol Metab 84:58–63. https://doi.org/10.1210/jcem.84.1.5374

82. Andiran N, Yardam N (2007) TNF-alpha levels in children with growth hormone deficiency and the effect of long-term growth hormone replacement therapy. Growth Horm IGF Res Off J

224 Pituitary (2022) 25:211–228
Growth Horm Res Soc Int IGF Res Soc 17:149–153. https://doi.org/10.1016/j.gihre.2007.01.002
83. Mezza C, Elshefy HH, Pagani S, Bozzola E, El Kholy M, Bozzola M (2014) Metabolic parameters and adipokine profile in growth hormone deficient (GHD) children before and after 12-month GH treatment. Horm Metab Res Hormstoffwechsel 5:219–223. https://doi.org/10.1055/s-0033-1358730
84. Yu X-H, He L-H, Gao J-H, Zhang D-W, Zheng X-L, Tang C-K (2018) Pregnancy-associated plasma protein-A in atherosclerosis: molecular marker, mechanistic insight, and therapeutic target. Atherosclerosis 278:250–258. https://doi.org/10.1016/j.atherosclerosis.2018.01.004
85. Joaquín C, Aguilar E, Granada ML, Pastor MC, Salinas I, Alonso N et al (2008) Effects of GH treatment in GH-deficient adults on adiponectin, leptin and pregnancy-associated plasma protein-A. Eur J Endocrinol 158:483–490. https://doi.org/10.1530/EJE-07-0554
86. Bale LK, Chakraborty S, Conover CA (2014) Inducible reduction in pregnancy-associated plasma protein-A gene expression inhibits its established atherosclerotic plaque progression in mice. Endocrinology 155:1184–1187. https://doi.org/10.1210/en.2013-2110
87. Li L, Ren W, Li J, Liu J, Wang L, Zheng X et al (2012) Increase in serum pregnancy-associated plasma protein-A is correlated with increase in cardiovascular risk factors in adult patients with growth hormone deficiency. Endocrine 42:375–381. https://doi.org/10.1007/s12020-012-9697-9
88. Willeit P, Freitag DF, Laukkanen JA, Chowdhury S, Gobin R, Yu X-H, He L-H, Gao J-H, Zhang D-W, Zheng X-L, Tang C-K (2012) Increase of adhesion dysfunction in adults with hypopituitarism and severe GH deficiency: different plasma antioxidant patterns in comparison with metabolic syndrome. Endocrine 59:130–136. https://doi.org/10.1007/s12020-017-1468-1
89. Mancini A, Di Segni C, Bruno C, Olivieri G, Guidi F, Silvestrini et al (2018) Oxidative stress in adult growth hormone deficiency: different plasma antioxidant patterns in comparison with metabolic syndrome. Clin Endocrinol (Oxf) 56:449–455. https://doi.org/10.1111/cen.13581
90. Evans LM, Davies JS, Anderson RA, Ellis GR, Jackson SK, Lewis MJ et al (2000) The effect of GH replacement therapy on endothelial function and oxidative stress in adult growth hormone deficiency. Eur J Endocrinol 142:254–262. https://doi.org/10.1530/eje.0.1420254
91. Smith JC, Lang D, McEneny J, Evans LM, Scanlon MF, Young et al (2006) Effects of GH on lipid peroxidation and neutrophil superoxide anion-generating capacity in hypopituitary adults with GH deficiency. Clin Endocrinol (Oxf) 56:449–455. https://doi.org/10.1111/j.1365-2265.2002.01493.x
92. Witkowski-Sędek E, Rumińska M, Stelmaszczyzk-Emmel A, Majcher A, Pyrzák B (2018) The associations between the growth hormone-insulin-like growth factor-1 axis, adiponectin, resistin and metabolic profile in children with growth hormone deficiency before and during growth hormone treatment. Acta Biochim Pol 65:333–340. https://doi.org/10.18388/abp.2018_2601
93. Orrù S, Negro E, Mandola A, Alfieri A, Buono P, Daniele A et al (2017) A Functional Interplay between IGF-1 and Adiponectin. Int J Mol Sci. https://doi.org/10.3390/ijms18102145
94. Berryman DE, List EO (2017) Growth hormone’s effect on adipose tissue: quality versus quantity. Int J Mol Sci. https://doi.org/10.3390/ijms18081621
95. Condise RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR et al (1996) Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 334:292–295. https://doi.org/10.1056/NEJM199602133340503
96. Fisker S, Vahl N, Hansen TB, Jørgensen JO, Hagen C, Orskov H et al (1997) Serum leptin is increased in growth hormone-deficient adults: relationship to body composition and effects of placebo-controlled growth hormone therapy for 1 year. Metabolism 46:812–817. https://doi.org/10.1016/s0026-0495(97)90128-1
97. Florkowski CM, Collier GR, Zimmet PZ, Livesey JH, Espiner EA, Donald RA (1996) Low-dose growth hormone replacement lowers plasma leptin and fat stores without affecting body mass index in adults with growth hormone deficiency. Clin Endocrinol (Oxf) 45:769–773. https://doi.org/10.1111/j.1365-2265.1996.830895.x
98. Fukuda I, Hizuka N, Ishikawa Y, Itoh E, Yamamoto K, Murakami Y et al (2004) Serum adiponectin levels in adult growth hormone deficiency and acromegaly. Growth Horm IGF Res Off J Growth
112. Tafere GG, Wondafrash DZ, Zewdie KA, Assefa BT, Ayza MA, Hana V, Silha JV, Justova V, Lacinova Z, Stepan JJ, Murphy Achari AE, Jain SK (2017) Adiponectin, a therapeutic target for obesity, diabetes, and endothelial dysfunction. Int J Mol Sci. https://doi.org/10.3390/ijms18061321

111. Giavoli C, Cappiello V, Corbetta S, Ronchi CL, Morpurgo PS, Ferrante E et al (2004) Different effects of short- and long-term recombinant hGH administration on ghrelin and adiponectin levels in GH-deficient adults. Clin Endocrinol (Oxf) 61:81–87. https://doi.org/10.1111/j.1365-2265.2004.02067.x

110. Hana V, Silha JV, Justova V, Lacinova Z, Stepan JJ, Murphy LJ (2004) The effects of GH replacement in adult GH-deficient patients: changes in body composition without concomitant changes in the adipokines and insulin resistance. Clin Endocrinol (Oxf) 60:442–450. https://doi.org/10.1111/j.1365-2265.2004.02000.x

109. Tafere GG, Wondafrash DZ, Zewdie KA, Assefa BT, Ayza MA, Hana V, Silha JV, Justova V, Lacinova Z, Stepan JJ, Murphy Achari AE, Jain SK (2017) Adiponectin, a therapeutic target for obesity, diabetes, and endothelial dysfunction. Int J Mol Sci. https://doi.org/10.3390/ijms18061321

108. Salvatori R (2015) Growth hormone deficiency in patients with obesity. Endocrinology, Japan Endocrine Society, and Endocrine Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia. Eur J Endocrinol 157:695–700. https://doi.org/10.1530/EJE-07-0631

107. Filippson Nystrom H, Barbosa EJL, Nilsson AG, Normann L-L, Ragnarsson O, Johannsson G (2012) Discontinuing long-term GH replacement therapy—a randomized, placebo-controlled crossover trial in adult GH deficiency. J Clin Endocrinol Metab 97:3185–3195. https://doi.org/10.1210/jc.2012-2006

106. de Koning L, Merchant AT, Pogue J, Anand SS (2007) Waist circumference and waist-to-hip ratio as predictors of cardiovascular events: meta-regression analysis of prospective studies. Eur Heart J 28:850–856. https://doi.org/10.1093/eurheartj/ehm026

105. Gerstein HC (1997) Glucose: a continuous risk factor for cardiovascular disease. Diabet Med J Br Diabet Assoc 14(Suppl 3):S25–S21. https://doi.org/10.1002/(sici)1096-9136(199708)14:3<+3::aid-diabetesdial1333.0.co;2-4

104. Prodam F, Vaztavaro M, Caputo M, Marzullo P, Aimaretti G (2014) Diabetes in growth hormone deficiency. Front Diabetes 22:10–21. https://doi.org/10.1159/000357243

103. Jeffcoate W (2002) Growth hormone therapy and its relationship to insulin resistance, glucose intolerance and diabetes mellitus: a review of recent evidence. Drug Saf 25:199–212. https://doi.org/10.1530/EC-18-0096

102. Zhou H, Sun L, Zhang S, Wang Y, Yang G (2021) Effect of long-term growth hormone replacement on glucose metabolism in adults with growth hormone deficiency: a systematic review and meta-analysis. Eur J Endocrinol 166:13–20. https://doi.org/10.1530/EJE-11-0558

101. Hoffman AR, Kunzle JE, Baptistia J, Baum HBA, Baumann GP, Biller BMK et al (2004) Growth hormone (GH) replacement therapy in adult-onset gh deficiency: effects on body composition in men and women in a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab 89:2048–2056. https://doi.org/10.1210/jc.2003-030346

100. Ho KKY (2007) GH Deficiency Consensus Workshop Participants. Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia. Eur J Endocrinol 157:695–700. https://doi.org/10.1530/EJE-07-0631

99. Attanasio AF, Jung H, Mo D, Chanson P, Bouillon R, Goédj MI, Wilkins SJ et al (2013) Prevalence of diabetes mellitus in 6050 hypopituitary patients with adult-onset GH deficiency before GH replacement: a KIMS analysis. Eur J Endocrinol 168:297–305. https://doi.org/10.1530/EJE-12-0807

98. Attanasio AF, Jung H, Mo D, Chanson P, Bouillon R, Ho KKY et al (2011) Prevalence and incidence of diabetes mellitus in adult patients on growth hormone replacement for growth hormone deficiency: a surveillance database analysis. J Clin Endocrinol Metab 96:2255–2261. https://doi.org/10.1210/jc.2011-0448

97. Wilson JR, Brown NJ, Nian H, Yu C, Bidlingmaier M, Devin JK (2018) Dipeptidyl peptidase-4 inhibition potentiates stimulated growth hormone secretion and vasodilation in women. J Am Heart Assoc 7:e008000. https://doi.org/10.1161/JAHA.117.008000

96. Attanasio AF, Mo D, Erfurth EM, Tan M, Ho KY, Kleinberg D et al (2010) Prevalence of metabolic syndrome in adult hypopituitary growth hormone (GH)-deficient patients before and after GH replacement. J Clin Endocrinol Metab 95:74–81. https://doi.org/10.1210/jc.2009-1326

95. Verhelst J, Mattsson AF, Camacho-Hübner C, Lugner A, Abs R (2018) The prevalence of the metabolic syndrome and associated cardiovascular complications in adult-onset GHD during GH replacement: a KIMS analysis. Endocr Connect 7:653–662. https://doi.org/10.1530/EC-18-0096
137. Kolotowska-Häggsström M, Mattsson AF, Shalet SM (2009) Assessment of quality of life in adult patients with GH deficiency: KIMS contribution to clinical practice and pharmacoeconomic evaluations. Eur J Endocrinol 161: S51–S64. https://doi.org/10.1530/EJE-09-0266

138. Loftus J, Camacho-Hubner C, Hey-Hadavi J, Goodrich K (2019) Targeted literature review of the humanistic and economic burden of adult growth hormone deficiency. Curr Med Res Opin 35:963–973. https://doi.org/10.1080/03007995.2018.1546682

139. Sin NL (2016) The protective role of positive well-being in cardiovascular disease: review of current evidence, mechanisms, and clinical implications. Curr Cardiol Rep 18:106. https://doi.org/10.1007/s11886-016-0792-z

140. Stabler B (2001) Impact of growth hormone (GH) therapy on quality of life along the lifespan of GH-treated patients. Horm Res Paediatr 56(suppl 1):55–58. https://doi.org/10.1159/000048136

141. Levine GN, Cohen BE, Commodore-Mensah Y, Fleury J, Huffman JC, Khalid U et al (2021) Psychological health, well-being, and the mind-heart-body connection: a scientific statement from the American Heart Association. Circulation 143:e763–e783. https://doi.org/10.1161/CIR.0000000000009947

142. Steptoe A, Kivimäki M (2013) Stress and cardiovascular disease: an update on current knowledge. Annu Rev Public Health 34:337–354. https://doi.org/10.1146/annurev-publhealth-031912-114452

143. van der Lely AJ, Janssen JM, Lamberts SW (1998) Adult vs childhood onset GHD: is there a real clinical difference? Growth Horm IGF Res Off J Growth Horm Res Soc Int IGF Res Soc 8(Suppl A):21–23. https://doi.org/10.1016/s1096-6374(98)80004-x

144. Koranyi J, Svensson J, Götherström G, Sunnerhagen KS, van Bunderen CC, van den Dries C1, Heymans MW, Franken AAM, Koppeschaar HPF, van der Lely AJ et al (2014) Effect of long-term GH replacement therapy on cardiovascular outcomes in isolated GH deficiency compared with multiple pituitary hormone deficiencies: a sub-analysis from the Dutch National Registry of Growth Hormone Treatment in Adults. Eur J Endocrinol 171:151–160. https://doi.org/10.1530/EJE-14-0069

145. Verweij T, Slagboom TNA, van Varsseveld NC, van der Lely A-J, Drent ML, van Bunderen CC (2021) Cardiovascular risk profile in growth hormone-treated adults with craniohypopituitarism compared to non-functioning pituitary adenoma: a national cohort study. Eur J Endocrinol 185:793–801. https://doi.org/10.1530/EJE-21-0419

146. Prolla E, Giavoli C, Bergamaschi S, Ferrante E, Malchiodi E, Sala E et al (2015) Analysis of short- and long-term metabolic effects of growth hormone replacement therapy in adult patients with craniohypopituitarism and non-functioning pituitary adenoma. J Endocrinol Invest 38:413–420. https://doi.org/10.1007/s40618-014-0196-0

147. Verhelst J, Kendall-Taylor P, Erfurth EM, Price DA, Geffner M, Kolotowska-Häggsström M et al (2005) Baseline characteristics and response to 2 years of growth hormone (GH) replacement of hypopituitary patients with GH deficiency due to adult-onset craniohypopituitarism in comparison with patients with nonfunctioning pituitary adenoma: data from KIMS (Pfizer International Metabolic Database). J Clin Endocrinol Metab 90:4636–4643. https://doi.org/10.1210/jc.2005-0185

148. Shalet SM (2010) Partial growth hormone deficiency in adults; should we be looking for it? Clin Endocrinol (Oxf) 73:432–435. https://doi.org/10.1111/j.1365-2265.2010.03809.x

149. Rochira V, Guaraldi G (2017) Growth hormone deficiency and human immunodeficiency virus. Best Pract Res Clin Endocrinol Metab 31:91–111. https://doi.org/10.1016/j.bpeek.2017.02.006

150. Arcopinto M, Salzano A, Giallauria F, Bossone E, Isgaard J, Marra AM et al (2017) Growth hormone deficiency is associated with worse cardiac function, physical performance, and outcome in chronic heart failure: insights from the T.O.S.C.A. GHD study. PLoS ONE 12:e0170058. https://doi.org/10.1371/journal.pone.0170058

151. Lo J, You SM, Wei J, Canavan B, Grispoon S (2009) Relationship of peak growth hormone to cardiovascular parameters, waist circumference, lipids and glucose in HIV-infected patients and healthy adults. Clin Endocrinol (Oxf) 71:815–822. https://doi.org/10.1111/j.1365-2265.2009.03603.x

152. Shabbaz S, Manicardi M, Guaraldi G, Raggi P (2015) Cardiovascular disease in human immunodeficiency virus infected patients: a true or perceived risk? World J Cardiol 7:633–644. https://doi.org/10.4330/wjc.v7.i10.633

153. Cittadini A, Saldamarco L, Marra AM, Arcopinto M, Carlo-magno G, Imbriaco M et al (2009) Growth hormone deficiency in patients with chronic heart failure and beneficial effects of its correction. J Clin Endocrinol Metab 94:3329–3336. https://doi.org/10.1210/jc.2009-0533

154. Salzano A, Cittadini A, Bossone E, Suzuki T, Heaney LM (2018) Multiple hormone deficiency syndrome: a novel topic in chronic heart failure. Future Sci OA 4:FSO311. https://doi.org/10.4155/fsoa-2018-0041

155. Napoli R, D’Assante R, Miniiero M, Salzano A, Cittadini A (2020) Anabolic deficiencies in heart failure: ready for prime time? Heart Fail Clin 16:11–21. https://doi.org/10.1016/j.hjcl.2019.08.012

156. Niebauer J, Pillaud CM, Clark AL, Strasburger CJ, Hooper J, Poole-Wilson PA et al (1998) Deficient insulin-like growth factor I in chronic heart failure predicts altered body composition, anabolic deficiency, cytokine and neurohumoral activation. J Am Coll Cardiol 32:393–397. https://doi.org/10.1016/S0735-1097(98)00226-5

157. Cittadini A, Marra AM, Arcopinto M, Bobbio E, Salzano A, Sirico D et al (2013) Growth hormone replacement delays the progression of chronic heart failure combined with growth hormone deficiency: an extension of a randomized controlled single-blind study. JACC Heart Fail 1:325–330. https://doi.org/10.1016/j.jchf.2013.04.003

158. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L et al (2015) Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr Off Publ Am Soc Echocardiogr 28:1-39.e14. https://doi.org/10.1016/j.echo.2014.10.003

159. Armstrong AC, Gidding S, Gjesdal O, Wu C, Bluemke DA, Lima JAC (2012) LV Mass assessed by echocardiography and CMR, cardiovascular outcomes, and medical practice. JACC Cardiovasc Imaging 5:837–848. https://doi.org/10.1016/j.jcim.2012.06.003

160. Klaeboe LG, Edvardsen T (2019) Echocardiographic assessment of left ventricular systolic function. J Echocardiogr 17:10–16. https://doi.org/10.1007/s12574-018-0405-5

161. Giovannini L, Tirabassi G, Muscoggiuri G, Di Somma C, Colao A, Balercia G (2015) Impact of adult growth hormone deficiency on metabolic profile and cardiovascular risk [Review]. Endocr J 62:1037–1048. https://doi.org/10.1507/endocrj.EJ15-0337

162. Fabiani I, Pugliese NR, Santini V, Conte L, Bello VD (2016) Speckle-tracking imaging, principles and clinical applications:
a review for clinical cardiologists. IntechOpen. https://doi.org/10.5772/64261

164. Nakai H, Takeuchi M, Nishikage T, Lang RM, Otsuji Y (2009) Subclinical left ventricular dysfunction in asymptomatic diabetic patients assessed by two-dimensional speckle tracking echocardiography: correlation with diabetic duration. Eur J Echocardiogr 10:926–932. https://doi.org/10.1093/ejehocard/epq97

165. Kalam K, Otahal P, Marwick TH (2014) Prognostic implications of global LV dysfunction: a systematic review and meta-analysis of normal longitudinal strain and ejection fraction. Heart Br Card Soc 100:1673–1680. https://doi.org/10.1161/heartjnl-2014-305538

166. Hundley WG, Bluemke DA, Finn JP, Flamg SD, Fogel MA, Friedrich MG et al (2010) ACCF/ACR/AHA/NASCI/SCMR 2010 expert consensus document on cardiovascular magnetic resonance: a report of the American College of Cardiology foundation task force on expert consensus documents. J Am Coll Cardiol 55:2614–2662. https://doi.org/10.1016/j.jacc.2009.11.011

167. Bellenger NG, Davies LC, Francis JM, Coats AJ, Pennell DJ (2000) Reduction in sample size for studies of remodeling in heart failure by the use of cardiovascular magnetic resonance. J Cardiovasc Magn Reson Off J Soc Cardiovasc Magn Reson 2:271–278. https://doi.org/10.3109/1097664009148691

168. Ordovas KG, Higgins CB (2011) Delayed contrast enhancement on MR images of myocardium: past, present, future. Radiology 261:358–374. https://doi.org/10.1148/radiol.11091882

169. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L et al (2020) 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J 41:111–188. https://doi.org/10.1093/eurheartj/ehz455

170. Johri AM, Nambi V, Naqvi TZ, Feinstein SB, Kim ESH, Park MM et al (2020) Recommendations for the assessment of carotid arterial plaque by ultrasound for the characterization of atherosclerosis and evaluation of cardiovascular risk: from the American Society of Echocardiography. J Am Soc Echocardiogr 33:917–933. https://doi.org/10.1016/j.echo.2020.04.021

171. Boulou NM, Gardin JM, Malik S, Postley J, Wong ND (2016) Carotid plaque characterization, stenosis, and intima-media thickness according to age and gender in a large registry cohort. Am J Cardiol 117:1185–1191. https://doi.org/10.1016/j.amjcard.2015.12.062

172. O’Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK (1999) Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 340:14–22. https://doi.org/10.1056/NEJM19990107340103

173. Stein JH, Korcacz CE, Hurst RT, Lonn E, Kendall CB, Mohler ER et al (2008) Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine. J Am Soc Echocardiogr Off Publ Am Soc Echocardiogr 21:93–111. https://doi.org/10.1016/j.echo.2007.11.011

174. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL et al (2016) 2016 European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention Rehabilitation (EACPR). Eur Heart J 37:2315–2381. https://doi.org/10.1093/eurheartj/ehw106

175. Niu J, Deng C, Zheng R, Xu M, Lu J, Wang T et al (2020) The association and predictive ability of ECG abnormalities with cardiovascular diseases: a prospective analysis. Glob Heart 15:59. https://doi.org/10.5334/gh.790

176. Jonas DE, Reddy S, Middleton JC, Barclay C, Green J, Baker C et al (2018) Screening for cardiovascular disease risk with resting or exercise electrocardiography: evidence report and systematic review for the US preventive services task force. JAMA 319:2315–2328. https://doi.org/10.1001/jama.2018.6897

177. Myerburg RJ (2018) The screening ECG and cardiac risks. JAMA 319:2277–2279. https://doi.org/10.1001/jama.2018.6766

178. Tanriverdi F, Eryol NK, Atmaca H, Unluhizarci K, Ozdogr u, Sarikaya I et al (2005) The effects of 12 months of growth hormone replacement therapy on cardiac autonomic tone in adults with growth hormone deficiency. Clin Endocrinol (Oxf) 62:706–712. https://doi.org/10.1111/j.1365-2265.2005.02283.x

179. Leong KS, Mann P, Wallymahmed M, MacFarlane IA, Wilding JP (2000) Abnormal heart rate variability in adults with growth hormone deficiency. J Clin Endocrinol Metab 85:628–633. https://doi.org/10.1210/jcem.85.2.6396

180. Leong KS, Mann P, Wallymahmed M, MacFarlane IA, Wilding JP (2001) The influence of growth hormone replacement on heart rate variability in adults with growth hormone deficiency. Clin Endocrinol (Oxf) 54:819–826. https://doi.org/10.1046/j.1365-2265.2001.01267.x

181. Unluhizarci K, Eryol NK, Tanriverdi F, Colak R, Topsakal R, Ozdogr u I et al (2002) The effects of growth hormone therapy on heart rate variability in adults with growth hormone deficiency. Curr Ther Res 63:421–429. https://doi.org/10.1016/S0011-393X(02)80048-0

182. Boschetti M, Casu M, Moretti S, Teti C, Albanese V, Albertelli M et al (2015) Autonomic nervous system and cardiovascular risk assessment during one year of growth hormone replacement therapy in adults with growth hormone deficiency. Horm Athens 14:134–141. https://doi.org/10.14310/horm.2002.1510

183. Gupta P, Patel C, Patel H, Narayanaswamy S, Malhotra B, Green JT et al (2008) Tp(-e)/QT ratio as an index of arrhythmogenesis. J Electrocardiol 41:567–574. https://doi.org/10.1016/j.jelectrocard.2008.07.016

184. Gürdal A, Eroğlu H, Helvaci F, Sümerkan MÇ, Kasali K, Çetin Ş et al (2017) Evaluation of Tp-e interval, Tp-e/QT ratio and Tp-e/QTc ratio in patients with subclinical hypothyroidism. Ther Adv Endocrinol Metab 8:25–32. https://doi.org/10.1177/20082246.0748423

185. Tokatli A, Kılıçaslan F, Alis M, Yiginer O, Uzun M (2016) Prolonged Tp-e interval, Tp-e/QT ratio and Tp-e/QTc ratio in patients with type 2 diabetes mellitus. Endocrinol Metab Seoul Korea 31:105–112. https://doi.org/10.3803/EnM.2016.31.1.105

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.